Statin Primary Prevention Trial in HIV Halted for Efficacy Statin Primary Prevention Trial in HIV Halted for Efficacy

Interim data from the REPRIEVE study showed that a daily statin cut the risk for cardiovascular events by 35% in adults with HIV at low to moderate CV risk.Medscape Medical News
Source: Medscape Pulmonary Medicine Headlines - Category: Respiratory Medicine Tags: Cardiology News Source Type: news